Markets:

Overview

News

Currencies

International

Treasuries

Can-Fite Biopharma Ltd Sponsored ADR (Israel) (NY:CANF)

0.1898 +0.0063 (+3.43%)

Streaming Delayed Price Updated: 1:19 PM EST, Dec 31, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Can-Fite Biopharma Ltd Sponsored ADR (Israel)

< Previous 1 2 3 4 Next >

Curious about the most active stocks on Friday? ↗

December 26, 2025

Friday's session is buzzing with activity. Check out the stocks that are attracting the most attention and driving market activity!

Via Chartmill

Top movers in Friday's session ↗

December 26, 2025

Keep an eye on the top gainers and losers in Friday's session, as they reflect the most notable price movements.

Via Chartmill

Traders are paying attention to the gapping stocks in Friday's session. ↗

December 26, 2025

Let's delve into the US markets on Friday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.

Via Chartmill

Can Fite Biofarma: Q4 Earnings Insights ↗

March 28, 2024

Via Benzinga

Recap: Can Fite Biofarma Q3 Earnings ↗

November 30, 2023

Via Benzinga

Can-Fite BioPharma Shares Surged 50% In Pre-Market On Brazilian Patent Win ↗

December 26, 2025

The company said it was granted a patent covering the use of its A3 adenosine receptor agonists for the treatment of sexual dysfunction in Brazil.

Via Stocktwits

Topics Intellectual Property

Stay updated with the stocks that are on the move in today's pre-market session. ↗

December 26, 2025

Discover the top movers in Friday's pre-market session and stay informed about market dynamics.

Via Chartmill

Let's take a look at the stocks that are in motion in today's session. ↗

December 24, 2025

Let's have a look at what is happening on the US markets one hour before the close of the markets on Wednesday. Below you can find the top gainers and losers in today's session.

Via Chartmill

Top movers in Wednesday's session ↗

December 24, 2025

Looking for insights into the US markets in the middle of the day on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Via Chartmill

Which stocks are gapping on Wednesday? ↗

December 24, 2025

Traders are paying attention to the gapping stocks in Wednesday's session. Let's dive into which stocks are experiencing notable gaps.

Via Chartmill

These stocks that are showing activity before the opening bell on Wednesday. ↗

December 24, 2025

Before the US market kicks off on Wednesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.

Via Chartmill

In today's session, these stocks are experiencing unusual volume. ↗

November 19, 2025

Let's explore the current happenings on the US markets on Wednesday. Below, you'll find the stocks exhibiting unusual volume in today's session.

Via Chartmill

Tuesday's after hours session: top gainers and losers ↗

November 18, 2025

As the regular session of the US market on Tuesday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.

Via Chartmill

Which stocks are most active on Tuesday? ↗

November 18, 2025

Discover the most active stocks in Tuesday's session. Stay informed about the stocks that are generating the most trading volume!

Via Chartmill

Let's uncover which stocks are experiencing notable gaps during today's session. ↗

November 18, 2025

Today's session on Tuesday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.

Via Chartmill

Dow Falls Over 300 Points; Home Depot Posts Downbeat Earnings ↗

November 18, 2025

Via Benzinga

Topics Stocks

These stocks that are showing activity before the opening bell on Tuesday. ↗

November 18, 2025

As the US market prepares to open on Tuesday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.

Via Chartmill

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

November 18, 2025

Via Benzinga

Stay updated with the stocks that are on the move in today's pre-market session. ↗

September 30, 2025

The US market is yet to commence its session on Tuesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.

Via Chartmill

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

September 30, 2025

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

August 22, 2025

Via Benzinga

Top movers in Monday's session ↗

July 28, 2025

Intrigued by the market activity one hour before the close of the markets on Monday? Uncover the key winners and losers of today's session in our insightful analysis.

Via Chartmill

12 Health Care Stocks Moving In Monday's Intraday Session ↗

July 28, 2025

Via Benzinga

Unusual volume stocks in Thursday's session ↗

March 20, 2025

Let's have a look at what is happening on the US markets on Thursday. Below you can find the stocks with an unusual volume in today's session.

Via Chartmill

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

March 19, 2025

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session ↗

June 14, 2024

Via Benzinga

Why AMMO Shares Are Trading Lower By Over 19%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

June 14, 2024

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

April 25, 2024

Via Benzinga

CANF Stock Earnings: Can Fite Biofarma Beats EPS, Beats Revenue for Q4 2023 ↗

March 28, 2024

CANF stock results show that Can Fite Biofarma beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.

Via InvestorPlace

Why Is Liver Cancer Focused Can-Fite BioPharma Stock Trading Higher Today? ↗

November 21, 2023

Can-Fite BioPharma Ltd (NYSE: CANF) announced that a patient who participated in the Phase 2 Liver Cancer Study and was treated with namodenoson had a complete response and overall survival of

Via Benzinga

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.